Inclusion Criteria:

- Has a biopsy-confirmed diagnosis of NHL

- Is in first or second complete remission or partial remission, defined for the
purpose of this study as complete or partial response following first- or second-line
therapy

- Treatment with an autologous peripheral HSC transplant is planned and the patient is
eligible for autologous transplantation

- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

- Has recovered from all acute toxic effects of prior chemotherapy or other cancer
treatment.

- Has an actual body weight <175% of their ideal body weight (IBW)

- The patient agrees to use a highly effective method of contraception from Day 1
through ≥3 months following plerixafor treatment.

Exclusion Criteria:

- Concurrent serious illness and pathological conditions

- Has undergone previous HSC collections or collection attempt

- Has had any autologous or allogeneic HSC transplant

- Has active central nervous system (CNS) involvement

- Bone marrow lymphoma cells involvement >20%, as assessed by bone marrow biopsy within
4 months before signing the ICF

- Has received radiation therapy to the pelvis

- Has a diagnosis of all leukemias including any type of CLL

- Active infection

- Pregnant or nursing

- Anticipated post-transplant chemotherapy and/or radiation therapy below the diaphragm

- Received any prior radio-immunotherapy

- Prior 1,3-bis(2-chloroethyl)-1-nitroso-urea (BCNU) within 6 weeks prior to first dose
of G-CSF

- Prior cancer therapy, other investigational therapy within 4 weeks prior to first
dose of G-CSF

- Prior granulocyte/macrophage-colony stimulating factor (GM-CSF) or pegfilgrastim
within 3 weeks prior to the first dose of G-CSF

- Prior G-CSF within 2 weeks prior to the first dose of G-CSF

- Inadequate organ funtion evidenced by unacceptable laboratory result